{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "CDR_parsing.ipynb",
      "provenance": [],
      "collapsed_sections": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "AlUCf37tREXN"
      },
      "outputs": [],
      "source": [
        "from hmac import new\n",
        "from itertools import count\n",
        "from operator import length_hint\n",
        "import pandas as pd\n",
        "import re"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "alphabets= \"([A-Za-z])\"\n",
        "prefixes = \"(Mr|St|Mrs|Ms|Dr)[.]\"\n",
        "suffixes = \"(Inc|Ltd|Jr|Sr|Co)\"\n",
        "starters = \"(Mr|Mrs|Ms|Dr|He\\s|She\\s|It\\s|They\\s|Their\\s|Our\\s|We\\s|But\\s|However\\s|That\\s|This\\s|Wherever)\"\n",
        "acronyms = \"([A-Z][.][A-Z][.](?:[A-Z][.])?)\"\n",
        "websites = \"[.](com|net|org|io|gov)\""
      ],
      "metadata": {
        "id": "_3uIW8u5T_5h"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "file = '/content/drive/MyDrive/Colab Notebooks/TEst tfm/DATASETS_CDR/CDR_DevelopmentSet.PubTator.txt'"
      ],
      "metadata": {
        "id": "XAWQX3iLUEC1"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "class Blocke:\n",
        "    \n",
        "    def __init__(self,texto,entidades,cids):\n",
        "        self.texto=texto\n",
        "        self.entidades=entidades\n",
        "        self.cids=cids"
      ],
      "metadata": {
        "id": "gnnSI9FtUX3r"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "class RE:\n",
        "    \n",
        "    def __init__(self,texto,entidad_1_nombre,entidad_1_id,entidad_1_tipo,entidad_2_nombre,entidad_2_id,entidad_2_tipo,relacion):\n",
        "        self.texto=texto\n",
        "        self.entidad_1_nombre=entidad_1_nombre\n",
        "        self.entidad_1_id=entidad_1_id\n",
        "        self.entidad_1_tipo=entidad_1_tipo\n",
        "        self.entidad_2_nombre=entidad_2_nombre\n",
        "        self.entidad_2_id=entidad_2_id\n",
        "        self.entidad_2_tipo=entidad_2_tipo\n",
        "        self.relacion=relacion"
      ],
      "metadata": {
        "id": "CCpVpWdAUZYQ"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def split_into_sentences(text):\n",
        "    text = \" \" + text + \"  \"\n",
        "    text = text.replace(\"\\n\",\" \")\n",
        "    text = re.sub(prefixes,\"\\\\1<prd>\",text)\n",
        "    text = re.sub(websites,\"<prd>\\\\1\",text)\n",
        "    if \"Ph.D\" in text: text = text.replace(\"Ph.D.\",\"Ph<prd>D<prd>\")\n",
        "    text = re.sub(\"\\s\" + alphabets + \"[.] \",\" \\\\1<prd> \",text)\n",
        "    text = re.sub(acronyms+\" \"+starters,\"\\\\1<stop> \\\\2\",text)\n",
        "    text = re.sub(alphabets + \"[.]\" + alphabets + \"[.]\" + alphabets + \"[.]\",\"\\\\1<prd>\\\\2<prd>\\\\3<prd>\",text)\n",
        "    text = re.sub(alphabets + \"[.]\" + alphabets + \"[.]\",\"\\\\1<prd>\\\\2<prd>\",text)\n",
        "    text = re.sub(\" \"+suffixes+\"[.] \"+starters,\" \\\\1<stop> \\\\2\",text)\n",
        "    text = re.sub(\" \"+suffixes+\"[.]\",\" \\\\1<prd>\",text)\n",
        "    text = re.sub(\" \" + alphabets + \"[.]\",\" \\\\1<prd>\",text)\n",
        "    if \"”\" in text: text = text.replace(\".”\",\"”.\")\n",
        "    if \"\\\"\" in text: text = text.replace(\".\\\"\",\"\\\".\")\n",
        "    if \"!\" in text: text = text.replace(\"!\\\"\",\"\\\"!\")\n",
        "    if \"?\" in text: text = text.replace(\"?\\\"\",\"\\\"?\")\n",
        "    text = text.replace(\".\",\".<stop>\")\n",
        "    text = text.replace(\"?\",\"?<stop>\")\n",
        "    text = text.replace(\"!\",\"!<stop>\")\n",
        "    text = text.replace(\"<prd>\",\".\")\n",
        "    sentences = text.split(\"<stop>\")\n",
        "    sentences = sentences[:-1]\n",
        "    sentences = [s.strip() for s in sentences]\n",
        "    return sentences"
      ],
      "metadata": {
        "id": "47n-TFQtUeIa"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_block(file):\n",
        "    dicttext = []\n",
        "    lines = []\n",
        "    with open (file) as fp:\n",
        "        for line in enumerate(fp.readlines()):            \n",
        "            if line[1] == \"\\n\": \n",
        "                dicttext.append(lines)\n",
        "                lines=[]\n",
        "            else:                \n",
        "                lines.append(line)\n",
        "    return(dicttext)"
      ],
      "metadata": {
        "id": "jocAkEU8Ujuz"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def texto_unificado(titulo_parser,cuerpo_parser):\n",
        "    titulo_split = titulo_parser[1].split(\"|t|\")\n",
        "    cuerpo_split = cuerpo_parser[1].split(\"|a|\")\n",
        "    return titulo_split[1] + cuerpo_split[1]"
      ],
      "metadata": {
        "id": "ZiW3OfkYUnLw"
      },
      "execution_count": 9,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_list_Block():\n",
        "    list_bloques = []    \n",
        "    for item in get_block(file):           \n",
        "        list_entidades=[]\n",
        "        list_relations = []\n",
        "        \n",
        "        for entity in item[2:]:\n",
        "            if \"CID\" in entity[1]:\n",
        "                get_cid_relations = entity[1].split(\"CID\")\n",
        "                delete_space=get_cid_relations[1].strip()\n",
        "                remplazar_comas=delete_space.replace('\\t',',')\n",
        "                array_entity_cid = remplazar_comas.split(',')\n",
        "                dict_relations = {\n",
        "                    'entity1_id':array_entity_cid[0],\n",
        "                    'entity2_id':array_entity_cid[1]\n",
        "                }\n",
        "                list_relations.append(dict_relations)                   \n",
        "            else:\n",
        "                split_text =entity[1].replace('\\t',',')\n",
        "                clear_text = split_text.strip().split(',')      \n",
        "                dict_entity = {\n",
        "                    'id':clear_text[len(clear_text)-1],\n",
        "                    'tipo':clear_text[len(clear_text)-2],\n",
        "                    'nombre':clear_text[3]\n",
        "                }\n",
        "                list_entidades.append(dict_entity)\n",
        "        \n",
        "        bloque = Blocke(texto_unificado(item[0],item[1]),list_entidades,list_relations)\n",
        "        list_bloques.append(bloque)\n",
        "    return list_bloques"
      ],
      "metadata": {
        "id": "HoHNwdLJUqeq"
      },
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_list_entity():\n",
        "    list_enty = []\n",
        "    tupla_parser = []\n",
        "    for blocke in get_list_Block():\n",
        "        for entyt in blocke.entidades:\n",
        "            if entyt['nombre'] not in tupla_parser:\n",
        "                tupla_parser.append(entyt['nombre'])\n",
        "                dict_entrys = {\n",
        "                    'id':entyt['id'],\n",
        "                    'tipo':entyt['tipo'],\n",
        "                    'nombre':entyt['nombre']\n",
        "                }\n",
        "                list_enty.append(dict_entrys)\n",
        "           \n",
        "    return list_enty"
      ],
      "metadata": {
        "id": "SbhvFWkpU0OL"
      },
      "execution_count": 11,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_data_entity(nombre,list_object):\n",
        "    id=\"\"\n",
        "    tipo = \"\"\n",
        "    for it in list_object:\n",
        "        if it['nombre'] == nombre:\n",
        "               id=it['id']\n",
        "               tipo = it['tipo']\n",
        "    \n",
        "    return id,tipo     "
      ],
      "metadata": {
        "id": "Qu-wnp7gU44A"
      },
      "execution_count": 12,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def insert_data_to_list():\n",
        "    list_object_RE = []\n",
        "    dict_entidades = get_list_entity()\n",
        "    for block in get_list_Block():\n",
        "        text_split = split_into_sentences(block.texto)    \n",
        "        for cids in block.cids:\n",
        "            lis_entity_search =[]\n",
        "            entidad1=[]\n",
        "            entidad2=[]\n",
        "            for entity in block.entidades:            \n",
        "                if entity['id'] == cids['entity1_id']:\n",
        "                    if entity['nombre'] not in entidad1:\n",
        "                        entidad1.append(entity['nombre'])\n",
        "                if entity['id'] == cids['entity2_id']: \n",
        "                    if entity['nombre'] not in entidad2:\n",
        "                        entidad2.append(entity['nombre'])\n",
        "            \n",
        "            for oracion in text_split:\n",
        "                for entidad_1_search in entidad1:\n",
        "                    for entidad_2_search in entidad2:\n",
        "                        if oracion.find(entidad_1_search) != -1 and oracion.find(entidad_2_search) != -1:\n",
        "                            id_entidad1,tipo_entidad_1 =get_data_entity(entidad_1_search,dict_entidades)\n",
        "                            id_entidad2,tipo_entidad_2 =get_data_entity(entidad_2_search,dict_entidades)\n",
        "                            newEntityObject = RE(oracion,entidad_1_search,id_entidad1,tipo_entidad_1,entidad_2_search,id_entidad2,tipo_entidad_2,\"1\")\n",
        "                            list_object_RE.append(newEntityObject)                            \n",
        "                        else:\n",
        "                            id_entidad1,tipo_entidad_1 =get_data_entity(entidad_1_search,dict_entidades)\n",
        "                            id_entidad2,tipo_entidad_2 =get_data_entity(entidad_2_search,dict_entidades)\n",
        "                            newEntityObject = RE(oracion,entidad_1_search,id_entidad1,tipo_entidad_1,entidad_2_search,id_entidad2,tipo_entidad_2,\"0\")\n",
        "                            list_object_RE.append(newEntityObject)\n",
        "    return list_object_RE"
      ],
      "metadata": {
        "id": "2GXNnpCEU9ow"
      },
      "execution_count": 13,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def main():  \n",
        "    count=1\n",
        "    df = pd.DataFrame(columns=['Sentence','entity_1_name','entity_1_id','entity_1_type','entity_2_name','entity_2_id','entity_2_type','label'])\n",
        "    print('Init ..............')     \n",
        "    for re_object in insert_data_to_list():\n",
        "        print('----------------   SENTENCE '+str(count)+'  -----------------')\n",
        "        print(\"Sentence: \"+re_object.texto)\n",
        "        print(\"Entity 1: \"+re_object.entidad_1_nombre)\n",
        "        print(\"Entity-ID 1: \"+re_object.entidad_1_id)\n",
        "        print(\"Entity-TIPO 1: \"+re_object.entidad_1_tipo)\n",
        "        print(\"Entity 2: \"+re_object.entidad_2_nombre)\n",
        "        print(\"Entity-ID 2: \"+re_object.entidad_2_id)\n",
        "        print(\"Entity-TIPO 2: \"+re_object.entidad_2_tipo)\n",
        "        print(\"label: \"+re_object.relacion)\n",
        "        count=count+1\n",
        "        df.loc[len(df)]=[re_object.texto,re_object.entidad_1_nombre,re_object.entidad_1_id,re_object.entidad_1_tipo,re_object.entidad_2_nombre,re_object.entidad_2_id,re_object.entidad_2_tipo,re_object.relacion]\n",
        "    df.to_csv('datset.csv',index=False,encoding='utf-8')"
      ],
      "metadata": {
        "id": "z9Pt3RQ-VEmY"
      },
      "execution_count": 21,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "main()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AEhiq96aVRQK",
        "outputId": "4cc53d46-3685-4b3f-9d5e-1f6f58d98233"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mSe han truncado las últimas 5000 líneas del flujo de salida.\u001b[0m\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28140  -----------------\n",
            "Sentence: 6% of implanted eyes.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28141  -----------------\n",
            "Sentence: 6% of implanted eyes.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28142  -----------------\n",
            "Sentence: Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28143  -----------------\n",
            "Sentence: Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28144  -----------------\n",
            "Sentence: 1% of eyes at 1 year.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28145  -----------------\n",
            "Sentence: 1% of eyes at 1 year.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28146  -----------------\n",
            "Sentence: The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28147  -----------------\n",
            "Sentence: The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28148  -----------------\n",
            "Sentence: 5%) was not different from that of implanted eyes not subjected to surgery (35.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28149  -----------------\n",
            "Sentence: 5%) was not different from that of implanted eyes not subjected to surgery (35.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28150  -----------------\n",
            "Sentence: 4%) (P = .\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28151  -----------------\n",
            "Sentence: 4%) (P = .\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28152  -----------------\n",
            "Sentence: 09).\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28153  -----------------\n",
            "Sentence: 09).\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28154  -----------------\n",
            "Sentence: CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.\n",
            "Entity 1: fluocinolone acetonide\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28155  -----------------\n",
            "Sentence: CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.\n",
            "Entity 1: FA\n",
            "Entity-ID 1: D005446\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: elevated intraocular pressure\n",
            "Entity-ID 2: D009798\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28156  -----------------\n",
            "Sentence: Pallidal stimulation: an alternative to pallidotomy?\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28157  -----------------\n",
            "Sentence: A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28158  -----------------\n",
            "Sentence: Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28159  -----------------\n",
            "Sentence: Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28160  -----------------\n",
            "Sentence: Pallidal stimulation has not met with the same success.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28161  -----------------\n",
            "Sentence: According to the literature pallidotomy improves the \"on\" symptoms of PD, such as dyskinesias, as well as the \"off\" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28162  -----------------\n",
            "Sentence: Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28163  -----------------\n",
            "Sentence: Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the \"freezing\" phenomenon in the lower limbs at the same time.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28164  -----------------\n",
            "Sentence: Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.\n",
            "Entity 1: levodopa\n",
            "Entity-ID 1: D007980\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: dyskinesias\n",
            "Entity-ID 2: D004409\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28165  -----------------\n",
            "Sentence: Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28166  -----------------\n",
            "Sentence: Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28167  -----------------\n",
            "Sentence: Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28168  -----------------\n",
            "Sentence: Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28169  -----------------\n",
            "Sentence: Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28170  -----------------\n",
            "Sentence: Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28171  -----------------\n",
            "Sentence: Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28172  -----------------\n",
            "Sentence: Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28173  -----------------\n",
            "Sentence: Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28174  -----------------\n",
            "Sentence: Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28175  -----------------\n",
            "Sentence: Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28176  -----------------\n",
            "Sentence: Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28177  -----------------\n",
            "Sentence: We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28178  -----------------\n",
            "Sentence: We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28179  -----------------\n",
            "Sentence: We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28180  -----------------\n",
            "Sentence: In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28181  -----------------\n",
            "Sentence: In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28182  -----------------\n",
            "Sentence: In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28183  -----------------\n",
            "Sentence: Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.\n",
            "Entity 1: Dexatrim\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28184  -----------------\n",
            "Sentence: Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.\n",
            "Entity 1: Phenylpropanolamine\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28185  -----------------\n",
            "Sentence: Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.\n",
            "Entity 1: PPA\n",
            "Entity-ID 1: D010665\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myocardial infarction\n",
            "Entity-ID 2: D009203\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28186  -----------------\n",
            "Sentence: Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28187  -----------------\n",
            "Sentence: Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28188  -----------------\n",
            "Sentence: Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28189  -----------------\n",
            "Sentence: Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28190  -----------------\n",
            "Sentence: They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28191  -----------------\n",
            "Sentence: They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28192  -----------------\n",
            "Sentence: This imagery resembled visual disturbances previously experienced as \"flashbacks\" related to prior LSD consumption.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28193  -----------------\n",
            "Sentence: This imagery resembled visual disturbances previously experienced as \"flashbacks\" related to prior LSD consumption.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28194  -----------------\n",
            "Sentence: Risperidone administration was continued and the visual disturbances gradually wore off.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28195  -----------------\n",
            "Sentence: Risperidone administration was continued and the visual disturbances gradually wore off.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28196  -----------------\n",
            "Sentence: During a six-month follow-up period, there was no recurrence of visual disturbances.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28197  -----------------\n",
            "Sentence: During a six-month follow-up period, there was no recurrence of visual disturbances.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28198  -----------------\n",
            "Sentence: This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28199  -----------------\n",
            "Sentence: This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28200  -----------------\n",
            "Sentence: Conclusions based on two case reports should be taken with appropriate caution.\n",
            "Entity 1: Risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28201  -----------------\n",
            "Sentence: Conclusions based on two case reports should be taken with appropriate caution.\n",
            "Entity 1: risperidone\n",
            "Entity-ID 1: D018967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: visual disturbances\n",
            "Entity-ID 2: D010468\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28202  -----------------\n",
            "Sentence: Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28203  -----------------\n",
            "Sentence: Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28204  -----------------\n",
            "Sentence: Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28205  -----------------\n",
            "Sentence: Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28206  -----------------\n",
            "Sentence: Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28207  -----------------\n",
            "Sentence: Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28208  -----------------\n",
            "Sentence: Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28209  -----------------\n",
            "Sentence: Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28210  -----------------\n",
            "Sentence: Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28211  -----------------\n",
            "Sentence: Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28212  -----------------\n",
            "Sentence: PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28213  -----------------\n",
            "Sentence: PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28214  -----------------\n",
            "Sentence: Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28215  -----------------\n",
            "Sentence: Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28216  -----------------\n",
            "Sentence: Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28217  -----------------\n",
            "Sentence: Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28218  -----------------\n",
            "Sentence: Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28219  -----------------\n",
            "Sentence: Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28220  -----------------\n",
            "Sentence: In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28221  -----------------\n",
            "Sentence: In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28222  -----------------\n",
            "Sentence: Thus, PARP activation contributes to the cardiotoxicity of DOX.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28223  -----------------\n",
            "Sentence: Thus, PARP activation contributes to the cardiotoxicity of DOX.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28224  -----------------\n",
            "Sentence: PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.\n",
            "Entity 1: doxorubicin\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28225  -----------------\n",
            "Sentence: PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.\n",
            "Entity 1: DOX\n",
            "Entity-ID 1: D004317\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: heart failure\n",
            "Entity-ID 2: D006333\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28226  -----------------\n",
            "Sentence: Fluconazole-induced torsade de pointes.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28227  -----------------\n",
            "Sentence: Fluconazole-induced torsade de pointes.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28228  -----------------\n",
            "Sentence: Fluconazole-induced torsade de pointes.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28229  -----------------\n",
            "Sentence: Fluconazole-induced torsade de pointes.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28230  -----------------\n",
            "Sentence: OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28231  -----------------\n",
            "Sentence: OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28232  -----------------\n",
            "Sentence: OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28233  -----------------\n",
            "Sentence: OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28234  -----------------\n",
            "Sentence: CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28235  -----------------\n",
            "Sentence: CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28236  -----------------\n",
            "Sentence: CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28237  -----------------\n",
            "Sentence: CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28238  -----------------\n",
            "Sentence: The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28239  -----------------\n",
            "Sentence: The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28240  -----------------\n",
            "Sentence: The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28241  -----------------\n",
            "Sentence: The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28242  -----------------\n",
            "Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28243  -----------------\n",
            "Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28244  -----------------\n",
            "Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28245  -----------------\n",
            "Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28246  -----------------\n",
            "Sentence: In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28247  -----------------\n",
            "Sentence: In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28248  -----------------\n",
            "Sentence: In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28249  -----------------\n",
            "Sentence: In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28250  -----------------\n",
            "Sentence: CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28251  -----------------\n",
            "Sentence: CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28252  -----------------\n",
            "Sentence: CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28253  -----------------\n",
            "Sentence: CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28254  -----------------\n",
            "Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28255  -----------------\n",
            "Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.\n",
            "Entity 1: Fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28256  -----------------\n",
            "Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28257  -----------------\n",
            "Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.\n",
            "Entity 1: fluconazole\n",
            "Entity-ID 1: D015725\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: TDP\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28258  -----------------\n",
            "Sentence: High-dose methylprednisolone may do more harm for spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28259  -----------------\n",
            "Sentence: High-dose methylprednisolone may do more harm for spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28260  -----------------\n",
            "Sentence: Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28261  -----------------\n",
            "Sentence: Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28262  -----------------\n",
            "Sentence: In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28263  -----------------\n",
            "Sentence: In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28264  -----------------\n",
            "Sentence: The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28265  -----------------\n",
            "Sentence: The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28266  -----------------\n",
            "Sentence: We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28267  -----------------\n",
            "Sentence: We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28268  -----------------\n",
            "Sentence: Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28269  -----------------\n",
            "Sentence: Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28270  -----------------\n",
            "Sentence: To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: myopathy\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28271  -----------------\n",
            "Sentence: To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.\n",
            "Entity 1: methylprednisolone\n",
            "Entity-ID 1: D008775\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: damage to the muscle\n",
            "Entity-ID 2: D009135\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28272  -----------------\n",
            "Sentence: Probing peripheral and central cholinergic system responses.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28273  -----------------\n",
            "Sentence: Probing peripheral and central cholinergic system responses.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28274  -----------------\n",
            "Sentence: OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28275  -----------------\n",
            "Sentence: OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28276  -----------------\n",
            "Sentence: This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28277  -----------------\n",
            "Sentence: This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28278  -----------------\n",
            "Sentence: Scopolamine was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28279  -----------------\n",
            "Sentence: Scopolamine was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28280  -----------------\n",
            "Sentence: DESIGN: Randomized double-blind controlled trial.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28281  -----------------\n",
            "Sentence: DESIGN: Randomized double-blind controlled trial.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28282  -----------------\n",
            "Sentence: PARTICIPANTS: Ten healthy elderly (mean age 70) and 9 young (mean age 33) volunteers.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28283  -----------------\n",
            "Sentence: PARTICIPANTS: Ten healthy elderly (mean age 70) and 9 young (mean age 33) volunteers.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28284  -----------------\n",
            "Sentence: INTERVENTIONS: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28285  -----------------\n",
            "Sentence: INTERVENTIONS: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28286  -----------------\n",
            "Sentence: The study involved 4 sessions.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28287  -----------------\n",
            "Sentence: The study involved 4 sessions.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28288  -----------------\n",
            "Sentence: In 1 session, tropicamide (20 microL, 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28289  -----------------\n",
            "Sentence: In 1 session, tropicamide (20 microL, 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28290  -----------------\n",
            "Sentence: 01%) was administered to one eye and placebo to the other.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28291  -----------------\n",
            "Sentence: 01%) was administered to one eye and placebo to the other.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28292  -----------------\n",
            "Sentence: In another session, tropicamide (20 microL, 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28293  -----------------\n",
            "Sentence: In another session, tropicamide (20 microL, 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28294  -----------------\n",
            "Sentence: 01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28295  -----------------\n",
            "Sentence: 01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28296  -----------------\n",
            "Sentence: 1%) to one eye and placebo to the other.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28297  -----------------\n",
            "Sentence: 1%) to one eye and placebo to the other.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28298  -----------------\n",
            "Sentence: All eye drops were given in a randomized order.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28299  -----------------\n",
            "Sentence: All eye drops were given in a randomized order.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28300  -----------------\n",
            "Sentence: In 2 separate sessions, a single dose of scopolamine (0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28301  -----------------\n",
            "Sentence: In 2 separate sessions, a single dose of scopolamine (0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28302  -----------------\n",
            "Sentence: 5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28303  -----------------\n",
            "Sentence: 5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28304  -----------------\n",
            "Sentence: OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28305  -----------------\n",
            "Sentence: OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28306  -----------------\n",
            "Sentence: RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28307  -----------------\n",
            "Sentence: RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28308  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28309  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28310  -----------------\n",
            "Sentence: The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28311  -----------------\n",
            "Sentence: The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28312  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28313  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28314  -----------------\n",
            "Sentence: Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28315  -----------------\n",
            "Sentence: Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28316  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28317  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28318  -----------------\n",
            "Sentence: CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28319  -----------------\n",
            "Sentence: CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28320  -----------------\n",
            "Sentence: Thus, pilocarpine may be useful to assess variations in central cholinergic function in elderly patients.\n",
            "Entity 1: Scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28321  -----------------\n",
            "Sentence: Thus, pilocarpine may be useful to assess variations in central cholinergic function in elderly patients.\n",
            "Entity 1: scopolamine\n",
            "Entity-ID 1: D012601\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: impairment in word recall\n",
            "Entity-ID 2: D008569\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28322  -----------------\n",
            "Sentence: Acetazolamide-induced Gerstmann syndrome.\n",
            "Entity 1: Acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28323  -----------------\n",
            "Sentence: Acetazolamide-induced Gerstmann syndrome.\n",
            "Entity 1: acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28324  -----------------\n",
            "Sentence: Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.\n",
            "Entity 1: Acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28325  -----------------\n",
            "Sentence: Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.\n",
            "Entity 1: acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28326  -----------------\n",
            "Sentence: We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.\n",
            "Entity 1: Acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28327  -----------------\n",
            "Sentence: We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.\n",
            "Entity 1: acetazolamide\n",
            "Entity-ID 1: D000086\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Gerstmann syndrome\n",
            "Entity-ID 2: D005862\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28328  -----------------\n",
            "Sentence: Hypomania-like syndrome induced by olanzapine.\n",
            "Entity 1: olanzapine\n",
            "Entity-ID 1: C076029\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Hypomania\n",
            "Entity-ID 2: D001714\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28329  -----------------\n",
            "Sentence: Hypomania-like syndrome induced by olanzapine.\n",
            "Entity 1: olanzapine\n",
            "Entity-ID 1: C076029\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypomania\n",
            "Entity-ID 2: D001714\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28330  -----------------\n",
            "Sentence: We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.\n",
            "Entity 1: olanzapine\n",
            "Entity-ID 1: C076029\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Hypomania\n",
            "Entity-ID 2: D001714\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28331  -----------------\n",
            "Sentence: We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.\n",
            "Entity 1: olanzapine\n",
            "Entity-ID 1: C076029\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypomania\n",
            "Entity-ID 2: D001714\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28332  -----------------\n",
            "Sentence: Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28333  -----------------\n",
            "Sentence: Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28334  -----------------\n",
            "Sentence: Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28335  -----------------\n",
            "Sentence: Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28336  -----------------\n",
            "Sentence: In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28337  -----------------\n",
            "Sentence: In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 1\n",
            "----------------   ORACION 28338  -----------------\n",
            "Sentence: Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28339  -----------------\n",
            "Sentence: Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28340  -----------------\n",
            "Sentence: Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28341  -----------------\n",
            "Sentence: Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28342  -----------------\n",
            "Sentence: 01).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28343  -----------------\n",
            "Sentence: 01).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28344  -----------------\n",
            "Sentence: This defect persisted when zymosan opsonized by control serum was used (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28345  -----------------\n",
            "Sentence: This defect persisted when zymosan opsonized by control serum was used (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28346  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28347  -----------------\n",
            "Sentence: 05).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28348  -----------------\n",
            "Sentence: Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28349  -----------------\n",
            "Sentence: Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28350  -----------------\n",
            "Sentence: Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28351  -----------------\n",
            "Sentence: Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28352  -----------------\n",
            "Sentence: 0005).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28353  -----------------\n",
            "Sentence: 0005).\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 0\n",
            "----------------   ORACION 28354  -----------------\n",
            "Sentence: These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute liver failure\n",
            "Entity-ID 2: D017114\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28355  -----------------\n",
            "Sentence: These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.\n",
            "Entity 1: paracetamol\n",
            "Entity-ID 1: D000082\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: ALF\n",
            "Entity-ID 2: D015760\n",
            "Entity-TIPO 2: Chemical\n",
            "label: 1\n",
            "----------------   ORACION 28356  -----------------\n",
            "Sentence: Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28357  -----------------\n",
            "Sentence: Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28358  -----------------\n",
            "Sentence: Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28359  -----------------\n",
            "Sentence: Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28360  -----------------\n",
            "Sentence: This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28361  -----------------\n",
            "Sentence: This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28362  -----------------\n",
            "Sentence: This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28363  -----------------\n",
            "Sentence: This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28364  -----------------\n",
            "Sentence: METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28365  -----------------\n",
            "Sentence: METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28366  -----------------\n",
            "Sentence: METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28367  -----------------\n",
            "Sentence: METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28368  -----------------\n",
            "Sentence: From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28369  -----------------\n",
            "Sentence: From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28370  -----------------\n",
            "Sentence: From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28371  -----------------\n",
            "Sentence: From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28372  -----------------\n",
            "Sentence: Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28373  -----------------\n",
            "Sentence: Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28374  -----------------\n",
            "Sentence: Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28375  -----------------\n",
            "Sentence: Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28376  -----------------\n",
            "Sentence: RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28377  -----------------\n",
            "Sentence: RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28378  -----------------\n",
            "Sentence: RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28379  -----------------\n",
            "Sentence: RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28380  -----------------\n",
            "Sentence: When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28381  -----------------\n",
            "Sentence: When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28382  -----------------\n",
            "Sentence: When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28383  -----------------\n",
            "Sentence: When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28384  -----------------\n",
            "Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28385  -----------------\n",
            "Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28386  -----------------\n",
            "Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28387  -----------------\n",
            "Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28388  -----------------\n",
            "Sentence: Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28389  -----------------\n",
            "Sentence: Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28390  -----------------\n",
            "Sentence: Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28391  -----------------\n",
            "Sentence: Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28392  -----------------\n",
            "Sentence: Ten subjects in each group reported side effects related to treatment.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28393  -----------------\n",
            "Sentence: Ten subjects in each group reported side effects related to treatment.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28394  -----------------\n",
            "Sentence: Ten subjects in each group reported side effects related to treatment.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28395  -----------------\n",
            "Sentence: Ten subjects in each group reported side effects related to treatment.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28396  -----------------\n",
            "Sentence: The side effect profiles of sertraline and of placebo were similar.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28397  -----------------\n",
            "Sentence: The side effect profiles of sertraline and of placebo were similar.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28398  -----------------\n",
            "Sentence: The side effect profiles of sertraline and of placebo were similar.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28399  -----------------\n",
            "Sentence: The side effect profiles of sertraline and of placebo were similar.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28400  -----------------\n",
            "Sentence: CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28401  -----------------\n",
            "Sentence: CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.\n",
            "Entity 1: haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28402  -----------------\n",
            "Sentence: CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cognitive impairment\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28403  -----------------\n",
            "Sentence: CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.\n",
            "Entity 1: Haloperidol\n",
            "Entity-ID 1: D006220\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Impairment of cognitive function\n",
            "Entity-ID 2: D003072\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28404  -----------------\n",
            "Sentence: Ciprofloxacin-induced nephrotoxicity in patients with cancer.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28405  -----------------\n",
            "Sentence: Ciprofloxacin-induced nephrotoxicity in patients with cancer.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28406  -----------------\n",
            "Sentence: Nephrotoxicity associated with ciprofloxacin is uncommon.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28407  -----------------\n",
            "Sentence: Nephrotoxicity associated with ciprofloxacin is uncommon.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28408  -----------------\n",
            "Sentence: Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28409  -----------------\n",
            "Sentence: Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28410  -----------------\n",
            "Sentence: Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28411  -----------------\n",
            "Sentence: Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28412  -----------------\n",
            "Sentence: Allergic interstitial nephritis is believed to be the underlying pathological-process.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28413  -----------------\n",
            "Sentence: Allergic interstitial nephritis is believed to be the underlying pathological-process.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28414  -----------------\n",
            "Sentence: Definitive diagnosis requires performance of renal biopsy, although this is not always feasible.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28415  -----------------\n",
            "Sentence: Definitive diagnosis requires performance of renal biopsy, although this is not always feasible.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28416  -----------------\n",
            "Sentence: An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.\n",
            "Entity 1: Ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28417  -----------------\n",
            "Sentence: An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.\n",
            "Entity 1: ciprofloxacin\n",
            "Entity-ID 1: D002939\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28418  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28419  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28420  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28421  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28422  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28423  -----------------\n",
            "Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28424  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28425  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28426  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28427  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28428  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28429  -----------------\n",
            "Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28430  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28431  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28432  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28433  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28434  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28435  -----------------\n",
            "Sentence: This article reports two cases of this complication and reviews all reported cases to date.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28436  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28437  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28438  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28439  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28440  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28441  -----------------\n",
            "Sentence: Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28442  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28443  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28444  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28445  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28446  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28447  -----------------\n",
            "Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28448  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28449  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28450  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28451  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28452  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28453  -----------------\n",
            "Sentence: In these patients, no other acute side effects of pentamidine were observed.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28454  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28455  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28456  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28457  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28458  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28459  -----------------\n",
            "Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28460  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28461  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28462  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28463  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: Pentamidine isethionate\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28464  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28465  -----------------\n",
            "Sentence: When QTc interval prolongation is observed, early magnesium supplementation is advocated.\n",
            "Entity 1: Pentamidine\n",
            "Entity-ID 1: D010419\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Torsade de pointes\n",
            "Entity-ID 2: D016171\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28466  -----------------\n",
            "Sentence: Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28467  -----------------\n",
            "Sentence: Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28468  -----------------\n",
            "Sentence: Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28469  -----------------\n",
            "Sentence: Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28470  -----------------\n",
            "Sentence: During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28471  -----------------\n",
            "Sentence: Plasma malondialdehyde, which was present in minimal amount at zero time (0.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28472  -----------------\n",
            "Sentence: 058 mumol/liter plasma; SD 0.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28473  -----------------\n",
            "Sentence: 015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28474  -----------------\n",
            "Sentence: 298 mumol/liter plasma; SD 0.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28475  -----------------\n",
            "Sentence: 078).\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28476  -----------------\n",
            "Sentence: Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28477  -----------------\n",
            "Sentence: The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.\n",
            "Entity 1: malondialdehyde\n",
            "Entity-ID 1: D008315\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral ischemia\n",
            "Entity-ID 2: D002545\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28478  -----------------\n",
            "Sentence: Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.\n",
            "Entity 1: echothiophate iodide\n",
            "Entity-ID 1: D004456\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: muscle weakness\n",
            "Entity-ID 2: D018908\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28479  -----------------\n",
            "Sentence: A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.\n",
            "Entity 1: echothiophate iodide\n",
            "Entity-ID 1: D004456\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: muscle weakness\n",
            "Entity-ID 2: D018908\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28480  -----------------\n",
            "Sentence: Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.\n",
            "Entity 1: echothiophate iodide\n",
            "Entity-ID 1: D004456\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: muscle weakness\n",
            "Entity-ID 2: D018908\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28481  -----------------\n",
            "Sentence: Acute renal failure in high dose carboplatin chemotherapy.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28482  -----------------\n",
            "Sentence: Acute renal failure in high dose carboplatin chemotherapy.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28483  -----------------\n",
            "Sentence: Acute renal failure in high dose carboplatin chemotherapy.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28484  -----------------\n",
            "Sentence: Acute renal failure in high dose carboplatin chemotherapy.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28485  -----------------\n",
            "Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28486  -----------------\n",
            "Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28487  -----------------\n",
            "Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28488  -----------------\n",
            "Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28489  -----------------\n",
            "Sentence: We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28490  -----------------\n",
            "Sentence: We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28491  -----------------\n",
            "Sentence: We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28492  -----------------\n",
            "Sentence: We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28493  -----------------\n",
            "Sentence: Acute renal failure developed followed by a slow partial recovery of renal function.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28494  -----------------\n",
            "Sentence: Acute renal failure developed followed by a slow partial recovery of renal function.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28495  -----------------\n",
            "Sentence: Acute renal failure developed followed by a slow partial recovery of renal function.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28496  -----------------\n",
            "Sentence: Acute renal failure developed followed by a slow partial recovery of renal function.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28497  -----------------\n",
            "Sentence: Possible contributing factors are discussed.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28498  -----------------\n",
            "Sentence: Possible contributing factors are discussed.\n",
            "Entity 1: carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28499  -----------------\n",
            "Sentence: Possible contributing factors are discussed.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28500  -----------------\n",
            "Sentence: Possible contributing factors are discussed.\n",
            "Entity 1: Carboplatin\n",
            "Entity-ID 1: D016190\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: acute renal failure\n",
            "Entity-ID 2: D058186\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28501  -----------------\n",
            "Sentence: Endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28502  -----------------\n",
            "Sentence: Endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28503  -----------------\n",
            "Sentence: Endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial cancer\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28504  -----------------\n",
            "Sentence: A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28505  -----------------\n",
            "Sentence: A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28506  -----------------\n",
            "Sentence: A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial cancer\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28507  -----------------\n",
            "Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28508  -----------------\n",
            "Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28509  -----------------\n",
            "Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial cancer\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28510  -----------------\n",
            "Sentence: Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28511  -----------------\n",
            "Sentence: Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial carcinoma\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28512  -----------------\n",
            "Sentence: Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.\n",
            "Entity 1: estrogens\n",
            "Entity-ID 1: D004967\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: endometrial cancer\n",
            "Entity-ID 2: D016889\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28513  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28514  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28515  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28516  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28517  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28518  -----------------\n",
            "Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28519  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28520  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28521  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28522  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28523  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28524  -----------------\n",
            "Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28525  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28526  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28527  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28528  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28529  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28530  -----------------\n",
            "Sentence: When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28531  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28532  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28533  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28534  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28535  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28536  -----------------\n",
            "Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28537  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28538  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28539  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28540  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28541  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28542  -----------------\n",
            "Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28543  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28544  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28545  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28546  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28547  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28548  -----------------\n",
            "Sentence: Our report provides direct evidence for this role.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28549  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28550  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28551  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28552  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28553  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28554  -----------------\n",
            "Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28555  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28556  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28557  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgen\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28558  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea syndrome\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28559  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: syndrome of obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28560  -----------------\n",
            "Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.\n",
            "Entity 1: androgens\n",
            "Entity-ID 1: D000728\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: obstructive sleep apnea\n",
            "Entity-ID 2: D020181\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28561  -----------------\n",
            "Sentence: Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28562  -----------------\n",
            "Sentence: Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28563  -----------------\n",
            "Sentence: Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28564  -----------------\n",
            "Sentence: Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28565  -----------------\n",
            "Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28566  -----------------\n",
            "Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28567  -----------------\n",
            "Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28568  -----------------\n",
            "Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28569  -----------------\n",
            "Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28570  -----------------\n",
            "Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28571  -----------------\n",
            "Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28572  -----------------\n",
            "Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28573  -----------------\n",
            "Sentence: Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28574  -----------------\n",
            "Sentence: Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28575  -----------------\n",
            "Sentence: Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28576  -----------------\n",
            "Sentence: Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28577  -----------------\n",
            "Sentence: Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28578  -----------------\n",
            "Sentence: Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28579  -----------------\n",
            "Sentence: Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28580  -----------------\n",
            "Sentence: Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28581  -----------------\n",
            "Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28582  -----------------\n",
            "Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28583  -----------------\n",
            "Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28584  -----------------\n",
            "Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28585  -----------------\n",
            "Sentence: However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28586  -----------------\n",
            "Sentence: However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.\n",
            "Entity 1: aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28587  -----------------\n",
            "Sentence: However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28588  -----------------\n",
            "Sentence: However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.\n",
            "Entity 1: puromycin aminonucleoside\n",
            "Entity-ID 1: D011692\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Proteinuria\n",
            "Entity-ID 2: D011507\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28589  -----------------\n",
            "Sentence: Epileptogenic properties of enflurane and their clinical interpretation.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28590  -----------------\n",
            "Sentence: Epileptogenic properties of enflurane and their clinical interpretation.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28591  -----------------\n",
            "Sentence: Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28592  -----------------\n",
            "Sentence: Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28593  -----------------\n",
            "Sentence: In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28594  -----------------\n",
            "Sentence: In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28595  -----------------\n",
            "Sentence: Until the cause of the seizures was correctly identified, the patient was inappropriately treated with anticonvulsants.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28596  -----------------\n",
            "Sentence: Until the cause of the seizures was correctly identified, the patient was inappropriately treated with anticonvulsants.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28597  -----------------\n",
            "Sentence: Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28598  -----------------\n",
            "Sentence: Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28599  -----------------\n",
            "Sentence: Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28600  -----------------\n",
            "Sentence: Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28601  -----------------\n",
            "Sentence: Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28602  -----------------\n",
            "Sentence: Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28603  -----------------\n",
            "Sentence: On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizures\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28604  -----------------\n",
            "Sentence: On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.\n",
            "Entity 1: enflurane\n",
            "Entity-ID 1: D004737\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: seizure\n",
            "Entity-ID 2: D012640\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28605  -----------------\n",
            "Sentence: Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28606  -----------------\n",
            "Sentence: Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28607  -----------------\n",
            "Sentence: Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28608  -----------------\n",
            "Sentence: Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28609  -----------------\n",
            "Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28610  -----------------\n",
            "Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28611  -----------------\n",
            "Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28612  -----------------\n",
            "Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28613  -----------------\n",
            "Sentence: We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28614  -----------------\n",
            "Sentence: We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28615  -----------------\n",
            "Sentence: We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28616  -----------------\n",
            "Sentence: We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28617  -----------------\n",
            "Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28618  -----------------\n",
            "Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28619  -----------------\n",
            "Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28620  -----------------\n",
            "Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28621  -----------------\n",
            "Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28622  -----------------\n",
            "Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated.\n",
            "Entity 1: tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28623  -----------------\n",
            "Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral lesions\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28624  -----------------\n",
            "Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated.\n",
            "Entity 1: Tiazofurin\n",
            "Entity-ID 1: C033706\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: cerebral abnormalities\n",
            "Entity-ID 2: D001927\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28625  -----------------\n",
            "Sentence: Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28626  -----------------\n",
            "Sentence: A double-blind placebo-controlled investigation of efficacy and safety.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28627  -----------------\n",
            "Sentence: The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28628  -----------------\n",
            "Sentence: Fifty-seven patients were sedated with diazepam for surgery under epidural anaesthesia.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28629  -----------------\n",
            "Sentence: Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28630  -----------------\n",
            "Sentence: The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28631  -----------------\n",
            "Sentence: No significant differences between the two groups were observed for mood rating, amnesia, or vital signs.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28632  -----------------\n",
            "Sentence: The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28633  -----------------\n",
            "Sentence: There was no evidence of reaction at the injection site.\n",
            "Entity 1: diazepam\n",
            "Entity-ID 1: D003975\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: amnesia\n",
            "Entity-ID 2: D000647\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28634  -----------------\n",
            "Sentence: Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28635  -----------------\n",
            "Sentence: The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28636  -----------------\n",
            "Sentence: Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28637  -----------------\n",
            "Sentence: However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28638  -----------------\n",
            "Sentence: Total tissue catecholamine content of the kidney on a molar basis was unchanged.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28639  -----------------\n",
            "Sentence: Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28640  -----------------\n",
            "Sentence: This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28641  -----------------\n",
            "Sentence: Propranolol had no effect on stimulus-induced overflow in either group.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28642  -----------------\n",
            "Sentence: Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28643  -----------------\n",
            "Sentence: In conclusion, chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28644  -----------------\n",
            "Sentence: However, neither alterations in prejunctional beta-adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28645  -----------------\n",
            "Sentence: Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.\n",
            "Entity 1: epinephrine\n",
            "Entity-ID 1: D004837\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: hypertensive\n",
            "Entity-ID 2: D006973\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28646  -----------------\n",
            "Sentence: Ocular manifestations of juvenile rheumatoid arthritis.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28647  -----------------\n",
            "Sentence: We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28648  -----------------\n",
            "Sentence: Thirty-six of the 210 patients (17.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28649  -----------------\n",
            "Sentence: 2%) developed iridocyclitis.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28650  -----------------\n",
            "Sentence: Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28651  -----------------\n",
            "Sentence: However, 30% of the patients developed uveitis after 16 years of age.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28652  -----------------\n",
            "Sentence: Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28653  -----------------\n",
            "Sentence: Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28654  -----------------\n",
            "Sentence: Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28655  -----------------\n",
            "Sentence: Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28656  -----------------\n",
            "Sentence: Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28657  -----------------\n",
            "Sentence: Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28658  -----------------\n",
            "Sentence: We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28659  -----------------\n",
            "Sentence: Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28660  -----------------\n",
            "Sentence: Typical keratoconjunctivitis sicca developed in three of the uveitis cases.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28661  -----------------\n",
            "Sentence: This association with uveitis and JRA was not noted previously.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28662  -----------------\n",
            "Sentence: Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.\n",
            "Entity 1: hydroxychloroquine\n",
            "Entity-ID 1: D006886\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: chorioretinopathy\n",
            "Entity-ID 2: D012164\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28663  -----------------\n",
            "Sentence: Water intoxication associated with oxytocin administration during saline-induced abortion.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28664  -----------------\n",
            "Sentence: Water intoxication associated with oxytocin administration during saline-induced abortion.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28665  -----------------\n",
            "Sentence: Water intoxication associated with oxytocin administration during saline-induced abortion.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28666  -----------------\n",
            "Sentence: Water intoxication associated with oxytocin administration during saline-induced abortion.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28667  -----------------\n",
            "Sentence: Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28668  -----------------\n",
            "Sentence: Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28669  -----------------\n",
            "Sentence: Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28670  -----------------\n",
            "Sentence: Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28671  -----------------\n",
            "Sentence: The mechanism of water intoxication is discussed in regard to these cases.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28672  -----------------\n",
            "Sentence: The mechanism of water intoxication is discussed in regard to these cases.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28673  -----------------\n",
            "Sentence: The mechanism of water intoxication is discussed in regard to these cases.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28674  -----------------\n",
            "Sentence: The mechanism of water intoxication is discussed in regard to these cases.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28675  -----------------\n",
            "Sentence: Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28676  -----------------\n",
            "Sentence: Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28677  -----------------\n",
            "Sentence: Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28678  -----------------\n",
            "Sentence: Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 1\n",
            "----------------   ORACION 28679  -----------------\n",
            "Sentence: The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28680  -----------------\n",
            "Sentence: The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28681  -----------------\n",
            "Sentence: The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28682  -----------------\n",
            "Sentence: The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28683  -----------------\n",
            "Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28684  -----------------\n",
            "Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28685  -----------------\n",
            "Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28686  -----------------\n",
            "Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28687  -----------------\n",
            "Sentence: The oxytocin should not be administered in excess of 36 hours.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28688  -----------------\n",
            "Sentence: The oxytocin should not be administered in excess of 36 hours.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28689  -----------------\n",
            "Sentence: The oxytocin should not be administered in excess of 36 hours.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28690  -----------------\n",
            "Sentence: The oxytocin should not be administered in excess of 36 hours.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28691  -----------------\n",
            "Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28692  -----------------\n",
            "Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.\n",
            "Entity 1: oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28693  -----------------\n",
            "Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: Water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n",
            "----------------   ORACION 28694  -----------------\n",
            "Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.\n",
            "Entity 1: Oxytocin\n",
            "Entity-ID 1: D010121\n",
            "Entity-TIPO 1: Chemical\n",
            "Entity 2: water intoxication\n",
            "Entity-ID 2: D014869\n",
            "Entity-TIPO 2: Disease\n",
            "label: 0\n"
          ]
        }
      ]
    }
  ]
}